Tech Company Financing Transactions
Sudo Biosciences Funding Round
Sudo Biosciences, based in Menlo Park, scored $116 million in funding from Enavate Sciences, TPG Rise Climate Fund and Eventide Asset Management.
Transaction Overview
Company Name
Announced On
12/20/2023
Transaction Type
Venture Equity
Amount
$116,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance two investigational TYK2 candidates into the clinic next year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Menlo Park, CA Undisclosed
USA
Menlo Park, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients' lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Byrd
Browse more venture capital transactions:
Prev: 12/20/2023: Phosphorus Cybersecurity venture capital transaction
Next: 12/20/2023: Peach Worlds venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs